Exhibit Explores Healing Power of Creating Artwork

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

LOS ANGELES--An exhibit featuring works by five women artists who have lived with cancer was displayed in conjunction with the 1998 Oncology Nursing Society and ASCO meetings.

LOS ANGELES--An exhibit featuring works by five women artists who have lived with cancer was displayed in conjunction with the 1998 Oncology Nursing Society and ASCO meetings.

Novartis Oncology sponsored the exhibit, entitled Medicine Cures the Body, Art Heals the Spirit, along with The Creative Center for Women With Cancer, a New York-based nonprofit organization founded on a belief in the healing power of creative activity. The exhibit is part of Novartis’ Living With Cancer initiative, which provides support to cancer patients, their families, and friends.

The artists include Lise Poirier (Figure1); photographer Susan B. Markisz; Robin Glazer, art director for The Creative Center; Susan Shatter, whose work is on display at the Art Institute of Chicago and other museums; and sculptor Leonda Finke (Figure 2).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content